RVTY

REVVITY, INC. (RVTY) - Form 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended July 5, 2026, and the six-month period ended on the same date. Revvity, Inc. is a leading provider of health science solutions, operating through two primary reportable segments: Life Sciences (products and services for life sciences customers) and Diagnostics (clinically-oriented tools for reproductive health and immunodiagnostics). The fiscal year 2026 is a 53-week year, whereas the prior fiscal year 2025 was a 52-week year.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 1% ($9.4M) in Q2 and 4% ($55.8M) for the six months compared to the prior year. The Diagnostics segment drove growth with a 5% increase in Q2, while Life Sciences revenue declined 2% in Q2 due to a drop in Software revenue.
• Margin Expansion: Consolidated gross margin improved by 260 basis points in Q2 (to 57.1%) and 40 basis points for the six months (to 55.8%). This was primarily driven by tariff refunds of $16.2 million recognized in Q2 and favorable product mix shifts.
• Restructuring Costs: Restructuring and other costs increased significantly to $35.5 million in Q2 (from $11.2M prior year) and $46.2 million for the six months (from $14.4M prior year). These charges relate to workforce reductions affecting approximately 5% of the workforce and facility consolidations.
• Acquisitions: The company acquired Advanced Chemistry Development Inc. ("ACD/Labs") in Q1 2026 for $72.0 million in cash plus up to $8.0 million in contingent consideration.
• Debt Repayment: In July 2026, the company repaid all outstanding 2026 Notes (€500 million principal, approx. $571.2 million) upon maturity.

Guidance, Outlook, and Risks

• Outlook: Management expects the effective tax rate on continuing operations to be approximately 20% for fiscal year 2026. No specific revenue or earnings guidance for the full year was provided in this text.
• Dividends: The Board declared a quarterly dividend of $0.07 per share for Q3 2026, payable in November 2026.
• Share Repurchases: Under a $1.0 billion program authorized in October 2025, the company repurchased $86.9 million of stock in the first six months of 2026. Approximately $792.7 million remains available.
• Strategic Divestiture: On July 31, 2026, the company entered a definitive agreement to divest its Immunodiagnostics business in China (approx. 6% of 2025 revenue), expected to close by end of 2027.
• Risks: Key risks include global economic conditions, government funding uncertainties for customers, supply chain disruptions, foreign currency fluctuations, and the integration of recent acquisitions. The company also faces potential environmental liabilities and litigation risks.

Investor Verification Checklist

• Tariff Refund Sustainability: Verify the timing and certainty of future tariff refunds, as $16.2 million was recognized in Q2 based on cash receipt, with additional recoveries remaining uncertain.
• Restructuring Impact: Monitor the execution of cost-saving initiatives and the timeline for realizing benefits from the 5% workforce reduction and facility consolidations.
• Software Segment Performance: Investigate the causes of the decline in the Life Sciences Software revenue, which offset growth in Life Sciences Solutions.
• China Divestiture: Track the progress of the Immunodiagnostics China divestiture and any potential regulatory hurdles or transaction costs.
• Debt Maturity Profile: Review the remaining debt schedule, noting the repayment of the 2026 Notes and the upcoming maturities of other senior unsecured notes (2028, 2029, 2031, 2051).